4Q Earnings: $410 million (loss of $3.4 billion 4Q24) ...

Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 41 tables and 85 figures, this 159-page report ?Asia Pacific Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

Pfizer Inc. (NYSE:PFE) reported fourth-quarter adjusted EPS of 63 cents, compared to 10 cents a year ago, beating the ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.9% year on year to $17.76 billion. On the other hand, the company ...

Diluted EPS of $0.63 On Track to Deliver Overall Net Cost Savings of Approximately $4.5 Billion by End of 2025 from Ongoing ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

Today, companies like Nestle India, Punjab National Bank, Marico, Vedanta, Pfizer, Oil and Natural Gas Corporation, and ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

The global market for Biological Drugs was estimated at US$345.3 Billion in 2023 and is projected to reach US$634.4 Billion by 2030, growing at a CAGR of 9.1% from 2023 to 2030. This comprehensive ...

Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...